AN ACT Relating to authorizing the use of epinephrine autoinjector devices through collaborative agreements; and adding a new section to chapter 70.54 RCW.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

NEW SECTION.  Sec. 1.  A new section is added to chapter 70.54 RCW to read as follows:

(1) The definitions in this subsection apply throughout this section unless the context clearly requires otherwise.

(a) "Eligible entity" means an entity or organization at or in connection with which allergens capable of causing anaphylaxis may be present including, but not limited to, restaurants, recreation camps, youth sports leagues, amusement parks, and sports arenas.

(b) "Emergency health care provider" means:

(i) A physician with knowledge and experience in the delivery of emergency care; or

(ii) A hospital licensed under chapter 70.41 RCW that provides emergency care.

(2) An eligible entity may purchase, acquire, possess, and use epinephrine autoinjector devices pursuant to a collaborative agreement with an emergency health care provider. The collaborative agreement must include a written agreement that incorporates written practice protocols and policies and procedures that ensure compliance with this section. The eligible entity must file a copy of the collaborative agreement with the department of health before using an epinephrine autoinjector device.

(3) The department of health must establish or approve a training course on the use of epinephrine autoinjector devices. Employees or volunteers of eligible entities must successfully pass the training course before they are able to use an epinephrine autoinjector device while performing service for the eligible entity. The department of health must also adopt rules on the maintenance and disposal of epinephrine autoinjector devices by eligible entities.

(4) Every use of an epinephrine autoinjector device by an employee or volunteer of an eligible entity must be immediately reported to the emergency health care provider.

--- END ---